









Markets
/
Stocks
/
nasdaq-goss
/

Gossamer Bio Inc

GOSS

2.260USD

-0.175-7.19%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

522.75MMarket Cap

LossP/E TTM



Gossamer Bio Inc

2.260

-0.175-7.19%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Gossamer Bio Inc

Currency: USD Updated: 2026-02-06

Key Insights

Gossamer Bio Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 89 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.38.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Gossamer Bio Inc's Score

Industry at a Glance

Industry Ranking

89 / 392

Overall Ranking

216 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Gossamer Bio Inc Highlights

StrengthsRisks

Gossamer Bio, Inc. is a late-stage, clinical biopharmaceutical company, which is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.

Fairly Valued

The company’s latest PE is -3.29, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 181.89M shares, decreasing 17.86% quarter-over-quarter.

Held by Paul Tudor Jones

Star Investor Paul Tudor Jones holds 50.10K shares of this stock.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

9.375

Target Price

+285.01%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Gossamer Bio Inc is 7.13, ranking 155 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 13.29M, representing a year-over-year increase of 40.23%, while its net profit experienced a year-over-year increase of 56.55%.

Score

Industry at a Glance

Previous score

7.13

Change



Financials

3.56

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.56

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.71

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.50

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.33

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Gossamer Bio Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Gossamer Bio Inc is 6.19, ranking 316 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.29, which is -90.93% below the recent high of -0.30 and -108.20% above the recent low of -6.84.

Score

Industry at a Glance

Previous score

6.19

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 89/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Gossamer Bio Inc is 8.40, ranking 124 out of 392 in the Biotechnology & Medical Research industry. The average price target is 9.00, with a high of 15.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.40

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

9.286

Target Price

+277.47%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Gossamer Bio Inc

GOSS

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Gossamer Bio Inc is 6.38, ranking 257 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.76 and the support level at 1.99, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.74

Change

-0.36

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.010

Sell

RSI(14)

38.145

Neutral

STOCH(KDJ)(9,3,3)

19.585

Sell

ATR(14)

0.241

Low Volatility

CCI(14)

-124.653

Sell

Williams %R

96.099

Oversold

TRIX(12,20)

-0.764

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

2.461

Sell

MA10

2.485

Sell

MA20

2.548

Sell

MA50

2.974

Sell

MA100

2.792

Sell

MA200

2.213

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Gossamer Bio Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 78.58%, representing a quarter-over-quarter increase of 2.06%. The largest institutional shareholder is The Vanguard, holding a total of 12.87M shares, representing 5.56% of shares outstanding, with 25.37% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

New Enterprise Associates (NEA)

18.09M

Octagon Capital Advisors LP

17.05M

-7.08%

The Vanguard Group, Inc.

Star Investors

12.01M

+5.25%

BlackRock Institutional Trust Company, N.A.

12.53M

+12.42%

ARCH Venture Partners

8.06M

Samsara BioCapital, LLC

6.13M

Palo Alto Investors LP

5.46M

-4.79%

Hasnain's family

5.41M

+7.39%

Invus Public Equities Advisors, LLC

5.21M

683 Capital Management LLC

5.06M

-20.20%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Gossamer Bio Inc is 3.90, ranking 115 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.93. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Gossamer Bio Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.